About mesoblast ltd - MESO
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.
MESO At a Glance
Mesoblast Ltd.
55 Collins Street
Melbourne, Victoria (VIC) 3000
| Phone | 61-3-9639-6036 | Revenue | 120.79M | |
| Industry | Biotechnology | Net Income | -57,756,862.54 | |
| Sector | Health Technology | 2026 Sales Growth | 603.529% | |
| Fiscal Year-end | 06 / 2027 | Employees | 108 | |
| View SEC Filings |
MESO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 14.504 |
| Price to Book Ratio | 3.087 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -41.429 |
| Enterprise Value to Sales | 14.707 |
| Total Debt to Enterprise Value | 0.072 |
MESO Efficiency
| Revenue/Employee | 1,118,399.794 |
| Income Per Employee | -534,785.764 |
| Receivables Turnover | 2.095 |
| Total Asset Turnover | 0.155 |
MESO Liquidity
| Current Ratio | 2.435 |
| Quick Ratio | 2.088 |
| Cash Ratio | 1.269 |
MESO Profitability
| Gross Margin | 84.095 |
| Operating Margin | -42.638 |
| Pretax Margin | -47.307 |
| Net Margin | -47.817 |
| Return on Assets | -7.415 |
| Return on Equity | -9.908 |
| Return on Total Capital | -8.302 |
| Return on Invested Capital | -8.551 |
MESO Capital Structure
| Total Debt to Total Equity | 22.402 |
| Total Debt to Total Capital | 18.302 |
| Total Debt to Total Assets | 16.471 |
| Long-Term Debt to Equity | 20.004 |
| Long-Term Debt to Total Capital | 16.343 |